Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals signed a licensing agreement with Shanghai JMT-Bio Technology, a unit of CSPC Pharmaceutical Group (HKG:1093), to develop, sell, and commercialize tumor-related drug JSKN003 in mainland China, according to a Sunday filing with the Hong Kong bourse.
JMT-Bio will obtain the exclusive license and sublicense rights to develop, sell, offer, and commercialize JSKN003 and will be the sole authorized marketer holder. JMT-Bio will bear further clinical development expenses for the drug. Alphamab will have the right to supply the drug outside JMT-Bio's territory, including Hong Kong, Taiwan, and Macau.
Alphamab will be entitled to 3.08 billion yuan, including 400 million yuan and 300 million in upfront and sales milestone payments. The company will also receive royalties on medication sales.
The pharmaceutical stocks were up nearly 39% in recent trading, while CSPC Pharma's shares rose over 5%.
Price (HKD): $4.24, Change: $+1.2, Percent Change: +38.56%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。